@Article{info:doi/10.2196/34874,
author="Fu, Leiwen
and Tian, Tian
and Yao, Kai
and Chen, Xiang-Feng
and Luo, Ganfeng
and Gao, Yanxiao
and Lin, Yi-Fan
and Wang, Bingyi
and Sun, Yinghui
and Zheng, Weiran
and Li, Peiyang
and Zhan, Yuewei
and Fairley, Christopher K
and Grulich, Andrew
and Zou, Huachun",
title="Global Pattern and Trends in Penile Cancer Incidence: Population-Based Study",
journal="JMIR Public Health Surveill",
year="2022",
month="Jul",
day="6",
volume="8",
number="7",
pages="e34874",
keywords="global burden; penile cancer; incidence; average annual percentage change; epidemiology",
abstract="Background: Penile cancer is a relatively rare genital malignancy whose incidence and mortality are rising in many countries. Objective: This study aims to assess the recent incidence and mortality patterns and incidence trends of penile cancer. Methods: The age-standardized incidence and mortality rates (ASIR and ASMR, respectively) of penile cancer in 2020 were estimated from the Global Cancer Registries (GLOBOCAN) database. Incidence trends of penile cancer from 1973 to 2012 were assessed in 44 populations from 43 countries using the Cancer Incidence in Five Continents plus (CI5plus) and the Nordic Cancer Registries (NORDCAN) databases. Average annual percentage change was calculated to quantify trends in ASIR using joinpoint regression. Results: Globally, the estimated ASIR and ASMR of penile cancer were 0.80 (per 100,000) and 0.29 (per 100,000) in 2020, equating to 36,068 new cases and 13,211 deaths in 2020, respectively. There was no significant correlation between the ASIR (P=.05) or ASMR (P=.90) and Human Development Index. In addition, 15 countries saw increasing ASIR for penile cancer, 13 of which were from Europe (United Kingdom, Lithuania, Norway, Estonia, Finland, Sweden, Cyprus, Netherlands, Italy, Croatia, Slovakia, Russia, and the Czech), and 2 from Asia (China and Israel). Conclusions: Although the developing countries still bear the higher incidence and mortality of penile cancer, the incidence is on the rise in most European countries. To mitigate the disease burden resulting from penile cancer, measures to lower the risk for penile cancers, including improving penile hygiene and male human papillomavirus vaccination, may be warranted. ",
issn="2369-2960",
doi="10.2196/34874",
url="https://publichealth.jmir.org/2022/7/e34874",
url="https://doi.org/10.2196/34874",
url="http://www.ncbi.nlm.nih.gov/pubmed/35793140"
}